- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07943897
PROTECT-HER KIT to Improve HPV Self-Sampling Uptake Among Women in Selangor (PROTECTHER KIT)
Development, Validation, and Evaluation of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) on HPV Self-Sampling Uptake Among the KOSPEN Community in Selangor: A Cluster Randomised Controlled Trial
This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.
The main questions this study aims to answer are:
Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?
Will the PROTECT-HER KIT improve cervical cancer awareness among participants?
Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?
To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.
Participants will:
Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.
Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.
Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.
Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.
The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: FAIRUZ ALIA RAFIAI
- Telefoonnummer: +60332584000
- E-mail: dr.fairuzalia@moh.gov.my
Studie Locaties
-
-
Putrajaya
-
Petaling Jaya, Putrajaya, Maleisië, 40000
- Pejabat Kesihatan Daerah Petaling
-
Contact:
- FAIRUZ ALIA RAFIAI
- Telefoonnummer: 60332584000
- E-mail: dr.fairuzalia@moh.gov.my
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Malaysian women aged 30-65 years.
- Residing in a participating KOSPEN locality in Selangor.
- Able to read and understand Malay.
- Never screened or overdue for cervical cancer screening according to current Malaysian guidelines.
- Own a smartphone with WhatsApp.
Exclusion Criteria:
- Physical or mental impairment preventing participation in study procedures.
- Declines to participate or provide informed consent.
- Diagnosed cervical cancer or precancerous cervical disease.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Screening
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PROTECT-HER KIT
Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders. |
Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0). |
|
Actieve vergelijker: Standard Ministry of Health Education
Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services. |
Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary: Cervical cancer awareness
Tijdsspanne: Baseline, 1 and 2 months
|
Cervical Cancer Awareness Scale (Cx-CAS), 15 items |
Baseline, 1 and 2 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary: Cervical cancer awareness
Tijdsspanne: Baseline, 1 and 2 months
|
Cervical Cancer Awareness Scale (Cx-CAS), 15 items |
Baseline, 1 and 2 months
|
|
Secondary: Protection motivation
Tijdsspanne: Baseline, 1 and 2 months
|
Adapted Malay PMT questionnaire, 24 items |
Baseline, 1 and 2 months
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Pathologische processen
- Ziekte attributen
- Infecties
- Virusziekten
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- DNA-virusinfecties
- Tumorvirusinfecties
- Pathologische aandoeningen, tekenen en symptomen
- Papillomavirus-infecties
Andere studie-ID-nummers
- NMRR ID-26-03000-XRM (IIR)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .